Pharvaris N.V. Stock Price, News & Analysis

Pharvaris (Nasdaq: PHVS) has achieved its target enrollment in the RAPIDe-1 Phase 2 study of PHVS416, focused on treating HAE attacks, with top-line data expected in 4Q22. Additionally, the company is enrolling patients in the Phase 2 HAE CHAPTER-1 study for prophylactic treatment, also anticipating data in 4Q22. Pharvaris reported a strong liquidity position with €194.8 million in cash as of March 31, 2022, though R&D and G&A expenses increased, leading to a loss of €16.0 million for Q1 2022.

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), has announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas from May 10-12, 2022. The company's presentation is scheduled for May 12, 2022, at 10:00 AM PDT (7:00 PM CEST). A live webcast will be accessible on its website, with a replay available for 30 days post-event.

Pharvaris (Nasdaq: PHVS), a clinical-stage company specializing in oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), announced its participation in two investor conferences in April 2022. The 21st Annual Needham Virtual Healthcare Conference will take place on April 11, 2022, at 2:45 PM CEST, while the Kempen 14th Life Sciences Conference is scheduled for April 21, 2022, at 3:00 PM CEST in Amsterdam. Investors can access webcasts of the presentations on the company's website, with replays available for 30 days post-event.

Pharvaris (PHVS) reported significant advancements in its clinical development, including the successful Phase 1 study of PHVS719, confirming its suitability for once-daily dosing. The FDA granted orphan drug designation to PHA121, enhancing its potential market position. Ongoing Phase 2 trials, RAPIDe-1 and CHAPTER-1, target on-demand and prophylactic treatment of hereditary angioedema (HAE), with top-line data expected in 4Q22. The company maintains a strong financial position with €209.4 million in cash, providing a runway into 1Q24.

Pharvaris has released pharmacological data on its novel bradykinin B2 receptor antagonist, PHA121. This compound demonstrates a 20-fold higher potency than icatibant, the only approved injectable B2 antagonist, while offering improved intrinsic clearance and oral bioavailability. The early clinical data indicates rapid absorption and favorable pharmacokinetics in healthy participants. Pharvaris aims to provide an oral treatment for hereditary angioedema (HAE), showcasing PHA121 as the most potent small-molecule antagonist in its category.

Pharvaris (Nasdaq: PHVS) announced participation in three investor conferences in March 2022. The events include:

• BioCapital Europe 2022 on March 10, 2022, at 3:00 PM CET in Amsterdam.
• Oppenheimer 32nd Annual Healthcare Conference via webcast on March 15, 2022, at 8:00 AM ET.
• SVB Leerink Mountain Meeting on March 22, 2022, at 9:30 AM MT in Jackson Hole, Wyoming.

Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference, occurring virtually from February 14–18, 2022. The fireside chat is set for February 16 at 4:40 PM CEST (10:40 AM EST). A live audio webcast will be accessible on the Investors section of their website, with a replay available for 30 days post-event. Pharvaris focuses on developing oral bradykinin-B2-receptor antagonists targeting hereditary angioedema and aims to provide alternatives to existing injected therapies.

Pharvaris (Nasdaq: PHVS) announced the appointment of Dr. Anne Marie de Jonge Schuermans to its board of directors, replacing Rémi Droller, effective December 22, 2021. Dr. de Jonge Schuermans, with extensive experience in biotech and pharmaceutical operations, will support Pharvaris as it prepares for commercialization of its oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema (HAE). The company anticipates a clinical data readout from Phase 2 trials within the next year, marking a pivotal step in its development strategy.

Pharvaris (Nasdaq: PHVS) has appointed Dr. Elisabeth Björk to its board of directors, effective December 1, 2021, to strengthen its leadership ahead of anticipated Phase 2 clinical data releases for hereditary angioedema (HAE) treatments. Dr. Björk, a seasoned expert in drug development at AstraZeneca, is set to replace Martijn Kleijwegt, who stepped down to focus on new investments. This leadership change aims to enhance Pharvaris’s capabilities as it prepares for commercialization of its bradykinin-B2-receptor antagonists candidates, PHVS416 and PHVS719, in the upcoming years.